NCT02182141View on ClinicalTrials.gov

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

March 31, 2005

Conditions
Multiple Myeloma
Interventions
DRUG

BIBF 1120 ES

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY